Suscribirse

Anticoagulation-associated Adverse Drug Events - 24/11/11

Doi : 10.1016/j.amjmed.2011.06.009 
Gregory Piazza, MD a, , Thanh Nha Nguyen, PharmD b, Deborah Cios, PharmD c, Matthew Labreche, PharmD b, Benjamin Hohlfelder b, John Fanikos, RPh, MBA c, Karen Fiumara, PharmD d, Samuel Z. Goldhaber, MD a
a Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 
b Venous Thromboembolism Research Group, Brigham and Women's Hospital, Boston, Mass 
c Department of Pharmacy, Brigham and Women's Hospital, Boston, Mass 
d Center for Clinical Excellence, Brigham and Women's Hospital, Boston, Mass 

Requests for reprints should be addressed to Gregory Piazza, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115

Abstract

Purpose

Anticoagulant drugs are among the most common medications that cause adverse drug events (ADEs) in hospitalized patients. We performed a 5-year retrospective study at Brigham and Women's Hospital to determine clinical characteristics, types, root causes, and outcomes of anticoagulant-associated ADEs.

Methods

We reviewed all inpatient anticoagulant-associated ADEs, including adverse drug reactions (ADRs) and medication errors, reported at Brigham and Women's Hospital through the Safety Reporting System from May 2004 to May 2009. We also collected data about the cost associated with hospitalizations in which ADRs occurred.

Results

Of 463 anticoagulant-associated ADEs, 226 were medication errors (48.8%), 141 were ADRs (30.5%), and 96 (20.7%) involved both a medication error and ADR. Seventy percent of anticoagulant-associated ADEs were potentially preventable. Transcription errors (48%) were the most frequent root cause of anticoagulant-associated medication errors, while medication errors (40%) were a common root cause of anticoagulant-associated ADRs. Death within 30 days of anticoagulant-associated ADEs occurred in 11% of patients. After an anticoagulant-associated ADR, most hospitalization expenditures were attributable to nursing costs (mean $33,189 per ADR), followed by pharmacy costs (mean $7451 per ADR).

Conclusion

Most anticoagulant-associated ADEs among inpatients result from medication errors and are, therefore, potentially preventable. We observed an elevated 30-day mortality rate among patients who suffered an anticoagulant-associated ADE and high hospitalization costs following ADRs. Further quality improvement efforts to reduce anticoagulant-associated medication errors are warranted to improve patient safety and decrease health care expenditures.

El texto completo de este artículo está disponible en PDF.

Keywords : Adverse drug events, Adverse drug reactions, Anticoagulation, Medication errors


Esquema


 Funding: Dr Piazza is supported by a Research Career Development Award (K12 HL083786) from the National Heart, Lung, and Blood Institute (NHLBI). This study was funded, in part, by a clinical research grant from Johnson & Johnson (New Brunswick, NJ).
 Conflict of Interest: None.
 Authorship: All authors had access to the data and played a role in writing this manuscript.


© 2011  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 124 - N° 12

P. 1136-1142 - décembre 2011 Regresar al número
Artículo precedente Artículo precedente
  • A Blast from the Past
  • Leann Silhan, Robert M. Reed
| Artículo siguiente Artículo siguiente
  • Venous Thromboembolism Prophylaxis for Medical Service—Mostly Cancer—Patients at Hospital Discharge
  • John Fanikos, Amanda Rao, Andrew C. Seger, Gregory Piazza, Elaine Catapane, Xiaohua Chen, Samuel Z. Goldhaber

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.